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In this issue of Cancer Cell, two groups present data on the function of an antagonist of BCL-2, ABT-737. Both groups find that 
expression of MCL-1, an antiapoptotic protein related to BCL-2, is a key determinant of resistance to ABT-737. Lowering MCL-1 
levels is an effective adjunct to BCL-2 antagonism, and both groups suggest ways that this might be accomplished practically in a 
clinical setting. The mechanism by which ABT-737 selectively kills cancer cells is discussed below in the context of these and prior 
reports of ABT-737’s function. Antagonism of BCL-2 is an exciting anticancer strategy that may soon become a clinical reality.Cancer cells get away with murder. In 
order to grow, spread, and, all too often, 
kill their hosts, cancer cells exhibit behav-cancer cell 10, November 2006 © 2006 eliors that ought to secure their own demise. 
For instance, genomic instability, onco-
gene activation, and anoikis, commonly Figure 1. Two models of bcl-2 inhibition of PcD
a: in model A, activator bH3-only proteins are sequestered by bcl-2 at the mitochondrion, preserving 
survival (aa) until treatment with AbT-737 displaces the activators, which then activate bAX or bAK, which 
oligomerize and induce momP (ab). When abundant mcl-1 is present, activator displaced from bcl-2 
by AbT-737 is bound by mcl-1, maintaining survival (ac and ad). 
B: in model b, bcl-2 and mcl-1 keep activated bAX or bAK at bay (Ba). AbT-737 frees bAX or bAK from 
bcl-2, allowing oligomerization and momP (Bb). When abundant mcl-1 is present, bAX or bAK displaced 
from bcl-2 can be bound by mcl-1 to prevent PcD (Bc and Bd).sevier iNc. exhibited by cancers, all provoke death 
signals that would kill ordinary cells, par-
ticularly by the mitochondrial, or intrinsic, 
pathway of programmed cell death (PCD). 
Yet cancer cells find a way to escape this 
death sentence. For this reason, it is 
widely believed that a block in PCD is a 
requirement for oncogenesis.
The BCL-2 protein blocks PCD. The 
bcl-2 gene was discovered as a par-
ticipant in the t(14;18) that drives BCL-
2 overexpression in follicular lymphoma 
cells, but BCL-2 expression is found in 
many tumor types. ABT-737 is a molecule 
that tightly binds and antagonizes the anti-
apoptotic function of BCL-2 and related 
proteins BCL-XL and BCL-w (Oltersdorf 
et al., 2005).
In order to understand how ABT-737 
kills cells, we must understand two com-
peting models of how BCL-2 (and related 
antiapoptotic proteins) oppose PCD. One 
model holds that prodeath “activator” 
BH3-only proteins, including BID and BIM, 
activate BAX or BAK to provoke mitochon-
drial outer membrane permeabilization 
(MOMP) (Certo et al., 2006; Kuwana et 
al., 2005; Letai et al., 2002). Binding and 
sequestering these activators before they 
can contact BAX or BAK is the key role for 
BCL-2 (and related antiapoptotic proteins) 
in this model (Figures 1Aa and 1Ac). In 
addition, BCL-2 may also bind BAX or 
BAK once they are activated. Cells with 
a significant amount of prodeath proteins 
held at bay by BCL-2 proteins we refer to 
as “primed.” Other “sensitizer” BH3-only 
family proteins cannot activate BAX or 
BAK but rather exert their prodeath func-
tion by competing for the hydrophobic 
cleft on BCL-2 that binds the activators, 
acting essentially as BCL-2 antagonists. 
An important criticism of this model, that 
an activating interaction between activa-
tor BH3-only molecules and BAX or BAK 
is difficult to observe directly, has been 
largely lifted by recent direct biochemi-
cal demonstrations of such an interaction 
(Oh et al., 2006; Walensky et al., 2006). 
In the competing model, BAX and BAK 
do not require activation by BH3-only 343
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always activated, and must thus be always 
bound and sequestered by BCL-2 (or 
related antiapoptotic proteins) to main-
tain survival (Chen et al., 2005; Willis et 
al., 2005) (Figures 1Ba and 1Bc). While 
binding of BAX or BAK to BCL-2 and other 
antiapoptotic proteins can be observed, 
the quantity of BAX or BAK bound gener-
ally represents the minority of the protein 
available, so that other interactions may 
also be important in keeping BAX and 
BAK in check. The BH3-only proteins in 
this model have no activator function, but 
rather act only as antagonists of the anti-
apoptotic proteins like BCL-2.
In an earlier study, an activator pro-
tein (BID) was indeed required for ABT-
737 to induce mitochondrial apoptosis 
(Supplemental Figure 3 in Oltersdorf et 
al., 2005). ABT-737 lacks the ability to 
directly activate BAX or BAK, defining it 
as a “sensitizer” BH3 mimetic (Certo et al., 
2006; Oltersdorf et al., 2005). In addition, 
we found that priming of BCL-2 with acti-
vators correlated with cellular sensitivity to 
ABT-737 (Certo et al., 2006). Thus, prior 
work has supported ABT-737’s operation 
through a mechanism consistent with 
model A (Figure 1A).
The current reports focus more on the 
role of MCL-1 in determining resistance to 
ABT-737 (van Delft et al., 2006; Konopleva 
et al., 2006). Both groups show in selected 
cell lines that high expression of MCL-1 
correlates with relative resistance to 
ABT-737. Both groups furthermore dem-
onstrate that reduction of MCL-1 levels 
significantly enhances sensitivity to ABT-
737. Both groups interpret this finding 
as supporting model B, in that it shows 
that loss of function of both MCL-1 and 
BCL-2 is needed to free BAX or BAK to 
induce apoptosis (Figures 1Bc and 1Bd). 
However, it must be noted that this find-
ing does not necessarily exclude opera-
tion according to the mechanism of model 
A. If activators are indeed critical to the 
activation of BAX or BAK, and they are 
displaced by ABT-737 from BCL-2, excess 
MCL-1 present would be able to buffer the 
death signal by sequestering activators 
(Figures 1Ac and 1Ad). Therefore, loss 
of MCL-1 would foster ABT-737 toxicity in 
either model.
Konopleva et al. perform additional 
experiments to investigate whether activa-
tor displacement is critical. They demon-
strate that ABT-737 disrupts interactions 
between BCL-2 and either BAX or BAK 
or BIM. When they knock down BIM in 
344 HL-60 cells, they show that there is little 
effect on apoptosis induced by ABT-737, 
suggesting that BIM plays little role in the 
apoptotic signaling. However, it is impor-
tant to observe that the knockdown of BIM 
is subtotal and has little effect on the tox-
icity of Taxol, which depends in part on 
BIM for death signaling. In addition, while 
BID and BIM are the only BCL-2 family 
members thus far identified as activators, 
it may be that other proteins with BAX- or 
BAK-activating function exist either in or 
out of the BCL-2 family.
An important issue for clinical use is 
whether ABT-737 selectively kills cancer 
cells. In an initial report, ABT-737 showed 
single-agent toxicity against chronic lym-
phocytic lymphoma cells, follicular lym-
phoma cells, lymphoma cell lines, and 
small-cell lung cancer cell lines. When 
tested in mouse xenograft models, tumor 
remission was observed, with observed 
toxicity to normal mouse tissues limited 
to lymphopenia and thrombocytopenia 
(Oltersdorf et al., 2005). Konopleva et al. 
use primary malignant cells obtained from 
patients with acute myelogenous leukemia 
to examine this issue. ABT-737 caused a 
dramatic reduction in colony formation in 
all five AML samples tested. Importantly, 
the effect on colony formation of normal 
bone marrow cells was much more mod-
est. Taken together, these two results 
demonstrate the presence of a therapeu-
tic window between normal and malignant 
myeloid bone marrow cells. As an interest-
ing adjunct, the authors also demonstrate 
that cells identified as leukemia stem cells 
are generally quite sensitive to ABT-737 
as well. This is an important observation, 
as it must be presumed that leukemia 
stem cells must also be killed if a thera-
peutic is expected to cure a malignancy. 
It will be very interesting to see whether 
the same observation can be made in vivo 
when such a drug makes its way into clini-
cal trials of AML.
What determines sensitivity to ABT-
737? In these two reports, a key factor 
seems to be lack of MCL-1. However, 
determination of sensitivity and resis-
tance may be a more complex matter. For 
instance, in the very AML experiments 
described above, the normal CD34+ bone 
marrow cells express a relatively modest 
level of MCL-1 protein yet show much less 
sensitivity to the drug than do the malig-
nant AML cells. In addition, a wide range 
of expression of BCL-2, MCL-1, and BAX 
can be observed across murine tissues. 
Yet normal tissues, with the exception of platelets and lymphocytes, are relatively 
insensitive to ABT-737 (Oltersdorf et al., 
2005). What other factors may be impor-
tant? A prior report points to the impor-
tance of priming BCL-2 with activator 
BH3-only proteins such as BIM to allow 
sensitivity to ABT-737 (Certo et al., 2006). 
Evidence is provided that cancer cells 
may in general be more primed than non-
malignant cells, explaining the observed 
therapeutic window. Whether this can be 
extended to a general predictor for cell 
toxicity to ABT-737 remains to be seen. It 
is also possible that explanations for dif-
ferent sensitivities between normal and 
malignant cells and explanations for differ-
ent sensitivities among various malignant 
cells may diverge.
While this preview has focused some-
what on competing ideas regarding the 
mechanism of ABT-737 function, it is 
important to summarize the very sig-
nificant points on which there appears to 
be general agreement. ABT-737 works 
through its expected mechanism of com-
peting for the BH3-binding cleft of BCL-
2 and displacing prodeath BCL-2 family 
members. High MCL-1 levels are likely to 
contribute to resistance to ABT-737. ABT-
737 has shown impressive single-agent 
toxicity in cell lines ex vivo and in vivo, 
and against primary human malignant 
cells. These areas of agreement alone are 
sufficient to prompt considerable excite-
ment at the prospect of adding such an 
interesting drug to our anticancer arma-
mentarium.
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Intrinsic tumor suppression pathways 
are innate, self-defeating programs that 
evolution has attached to those engines 
of cell expansion whose unbridled activi-
ties would otherwise constitute severe 
neoplastic risk (Lowe et al., 2004). Early 
examples included the unexpected pro-
pensity for activated RAS to induce growth 
arrest and the equally paradoxical procliv-
ity of MYC to drive apoptosis. Such obser-
vations are now understood as examples 
of how the mitogenic actions of individual 
oncoproteins can be exploited by the cell 
only when their inherent growth-inhibi-
tory properties are quelled by collateral 
signals. In the classical paradigm of onco-
gene cooperation, such obligate collateral 
signals are provided by the collaborat-
ing oncogene: hence, each oncogenic 
lesion is dependent on the properties of 
the other for its oncogenic potential to be 
manifest. Thus, the tumor phenotype is an 
emergent property of oncogenic lesions 
acting in concert (Evan and Littlewood, 
1998)—something a geneticist might term 
“synthetic viability” (Figure 1A).
Such observations offered the earli-
est clue that tumor cells might be preter-
naturally dependent for their survival upon 
the aberrant signaling networks that drive 
them, by suggesting that cutting individual 
oncogenic cords within the tumor ensem-
ble can expose the latent intrinsic tumor 
suppression pathways directed by any 
remaining oncogenic lesions. On the other 
hand, since oncogenes harbor the seeds 
of their own destruction, such ideas also 
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that inactivation of individual oncogenes 
might actually accentuate tumor growth 
by staunching the associated intrinsic 
tumor suppressor pathway. Only with the 
advent of reversibly switchable transgenic 
mouse cancer models, in which the activi-
ties of a specific oncogene targeted to a 
specific tissue can be toggled on and off 
at will, could the net consequences of 
acute oncogene ablation be directly test-
ed in vivo. Such animals are, in essence, 
genetic surrogates for targeted drugs, 
which can be used to establish the extent 
to which maintenance of experimental 
tumors remains dependent upon the onco-
genic mutations that drove their evolution, 
and what the nature of that dependency 
might be. Such in vivo studies indicated 
that deactivation of pivotal oncogenic 
mutations typically triggered profound 
tumor apoptosis that would frequently 
(Chin et al., 1999; Felsher and Bishop, 
1999; Fisher et al., 2001; Pelengaris et al., 
1999, 2002), but not always (Boxer et al., 
2004), lead to marked tumor regression. 
Even though such regression was often 
superseded by the emergence of resistant 
clones, such studies confirmed, in prin-
ciple, the idea that tumor cells acquire de 
novo a dependence upon the lesions that 
drive and maintain them. With the advent 
of targeted cancer therapies, it has finally 
become possible to explore this idea in 
human cancers in vivo, and the successful 
treatment of CML with Gleevec is the post-
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dency on oncogenic mutations holds for 
spontaneously occurring human cancers. 
Naysayers may point to the fact that resis-
tant clones eventually cause relapse of 
Gleevec-treated patients. However, even 
here the news is good: the great major-
ity of relapses involve resistant mutations 
in the ABL kinase rather than wholesale 
replacement of ABL by a newly evolved 
oncogenic edifice (Shah and Sawyers, 
2003). This suggests that dependence 
upon ABL is, indeed, profound and that, 
notwithstanding the genomic instability 
that characterizes the accelerated phase 
of CML, room for evolutionary maneuver 
by surviving tumor cells is extremely con-
strained.
Why should tumor cells acquire a 
dependence upon their oncogenic muta-
tions? The answer seems fairly straight-
forward in situations where an oncogenic 
mutation confers survival properties on 
the cell—for example, overexpression of 
BCL-2/BCL-xL, or constitutive signaling 
through survival factors receptors and 
their intracellular transducers. In such 
cases, removal of the constitutive survival 
signal exposes the targeted tumor cell to 
the full onslaught of preexisting proapop-
totic flux rife in cancers—hypoxic and 
nutrient-poor microenvironments, internal 
havoc wrought of genotoxic injuries and 
aberrant protein folding, and the continu-
ous pumping of apoptotic pathways by 
proproliferative mutations like activated 
MYC and E2F or loss of RB. By contrast, 
the dependence that tumor cells exhibit for 
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is strategy is that maintenance of human 
ns. In this issue of Cancer Cell, an intrigu-
ears to be working for us. They show that 
bition in favor of cell death. This bias may 
